IDEXX Laboratories reports company news centered on veterinary diagnostics, software and animal-health testing. Recurring updates cover CAG Diagnostics recurring revenue, reference laboratory services, in-clinic analyzers, premium instrument placements and financial guidance tied to veterinary practice demand in the U.S. and international regions.
Company announcements also describe product innovation across pet healthcare, including IDEXX Cancer Dx testing, IDEXX inVue Dx, digital imaging systems such as Vue DR50 Plus, Web PACS software and connected workflow tools for veterinary practices. Other recurring topics include investor conference participation, governance and leadership updates, and products that support milk and water safety and livestock health.
IDEXX (NASDAQ: IDXX) announced a planned CEO succession: Michael Erickson, PhD, will become President and CEO effective May 12, 2026, and will join the Board upon assuming the role. Current President and CEO Jonathan (Jay) Mazelsky will transition to Executive Chair at that time and has said he will retire following the Company’s annual meeting of shareholders in May 2027. The company described an extended transition with Mazelsky working closely with Erickson to support continuity. Erickson joined IDEXX in 2011 and has held senior roles across diagnostics, software, strategy, and corporate accounts.
IDEXX Laboratories (NASDAQ: IDXX) will release its 2025 fourth quarter and full year financial results on Monday, February 2, 2026 before market open. An analyst conference call will begin at 8:30 a.m. ET that day and will be available via a live webcast, telephone, and an archived webcast posted after 1:00 p.m. ET that will remain available for one year.
Investors can access the live webcast, a transcript of prepared remarks, and a Q4 2025 Earnings Snapshot from the company investor site at www.idexx.com/investors. To join the live call by phone dial 1-800-330-6730 or 1-213-279-1575 and reference passcode 263206.
Summary not available.
Bonsai Health named Rick Trefzger Chief Revenue Officer on October 16, 2025, after nearly 11 years at Modernizing Medicine and a recent vice president role at IDEXX (Nasdaq: IDXX). Trefzger will oversee all go-to-market functions including sales, marketing, and business development to expand Bonsai’s presence across medical specialties.
The appointment follows a $7 million seed raise led by Bonfire Ventures and Wonder Ventures as Bonsai scales its agentic AI platform to reduce administrative burden and improve patient outcomes.
IDEXX Laboratories (NASDAQ: IDXX) will release its 2025 third quarter financial results on Monday, November 3, 2025 before market open. An analyst conference call will begin at 8:30 a.m. ET that day.
Investors can access a live webcast, transcript of prepared remarks, and the Q3 2025 Earnings Snapshot at www.idexx.com/investors. An archived webcast will be available after 1:00 p.m. ET on November 3 and will remain online for one year. The live call is also available by telephone at 1-800-330-6730 or 1-213-279-1575 using passcode 300701.
IDEXX Laboratories (NASDAQ: IDXX) announced the election of Karen Peacock to its Board of Directors, effective October 6, 2025. The board chair said Peacock brings deep B2B, SaaS and AI experience.
Background highlights: former CEO of Intercom; ~14 years at Intuit including SVP of Small Business; current lead independent director at Dropbox; Harvard BA and Stanford MBA. Peacock said she looks forward to supporting IDEXX's diagnostics, software and AI efforts for veterinary practices.
IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. CEO Jay Mazelsky and CFO Andrew Emerson will engage in a fireside chat on September 9, 2025, from 1:50 PM to 2:25 PM ET.
Investors can access the live audio webcast through the company's investor relations website at www.idexx.com/investors. An archived version of the presentation will also be made available after the event.
IDEXX Laboratories (NASDAQ: IDXX) reported strong Q2 2025 results with 11% revenue growth to $1,109 million and EPS of $3.63, up 49% as reported. The company's performance was driven by 9% organic growth in Companion Animal Group (CAG) Diagnostics recurring revenue and record quarterly instrument placements, including nearly 2,400 IDEXX inVue Dx™ units.
IDEXX increased its 2025 revenue guidance to $4,205-$4,280 million, reflecting a $90 million increase at midpoint. The company also raised its EPS outlook to $12.40-$12.76, a $0.40 increase from previous guidance, supported by improved revenue outlook, operating margin expansion, and favorable tax rates.
IDEXX Laboratories (Nasdaq: IDXX), a leading pet healthcare innovator, has released its 2024 Corporate Responsibility Report highlighting significant achievements across three key pillars. The company launched groundbreaking innovations including the IDEXX inVue Dx™ Cellular Analyzer and IDEXX Cancer Dx™ testing for early cancer detection in pets.
Notable accomplishments include supporting over 79,000 animals in underserved communities, providing $5.5 million in continuing education credits, and achieving an 80% employee engagement rate. Environmental initiatives featured signing three virtual power purchase agreements and maintaining a 35% electric and hybrid commercial fleet. The company serviced over 34,000 instruments and completed 90,000 point-of-service upgrades to advance product circularity.
IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, has announced the appointment of Joseph L. (Jay) Hooley to its Board of Directors, effective July 10, 2025. Hooley, the former Chair and CEO of State Street Corporation, brings extensive strategic and financial leadership experience to IDEXX.
Hooley currently serves as lead independent director at Exxon Mobil Corporation and is on the board of Aptiv PLC. With his addition, the IDEXX Board now consists of ten directors, with nine being independent. His appointment strengthens the board's expertise in corporate governance and global business operations.